Competition is close for top positions
Pharmaceutical companies continue to inch forward in addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.
1 | GlaxoSmithKline plc |
0
1
2
3
4
5
|
3.67 | |
GlaxoSmithKline plcRead more |
||||
2 | Johnson & Johnson |
0
1
2
3
4
5
|
3.33 | |
Johnson & JohnsonRead more |
||||
3 | Novartis AG |
0
1
2
3
4
5
|
3.26 | |
Novartis AGRead more |
||||
4 | Sanofi |
0
1
2
3
4
5
|
2.83 | |
SanofiRead more |
||||
5 | Merck KGaA (Merck) |
0
1
2
3
4
5
|
2.79 | |
Merck KGaA (Merck)Read more |
||||
6 | AstraZeneca plc |
0
1
2
3
4
5
|
2.78 | |
AstraZeneca plcRead more |
||||
7 | Pfizer Inc. |
0
1
2
3
4
5
|
2.73 | |
Pfizer Inc.Read more |
||||
8 | Takeda Pharmaceutical Co. Ltd. |
0
1
2
3
4
5
|
2.71 | |
Takeda Pharmaceutical Co. Ltd.Read more |
||||
9 | Roche Holding AG |
0
1
2
3
4
5
|
2.54 | |
Roche Holding AGRead more |
||||
10 | Eisai Co. Ltd. |
0
1
2
3
4
5
|
2.11 | |
Eisai Co. Ltd.Read more |
||||
11 | Boehringer Ingelheim GmbH |
0
1
2
3
4
5
|
1.77 | |
Boehringer Ingelheim GmbHRead more |
||||
12 | AbbVie Inc. |
0
1
2
3
4
5
|
1.75 | |
AbbVie Inc.Read more |
||||
13 | Gilead Sciences Inc. |
0
1
2
3
4
5
|
1.71 | |
Gilead Sciences Inc.Read more |
||||
14 | Astellas Pharma Inc. |
0
1
2
3
4
5
|
1.32 | |
Astellas Pharma Inc.Read more |
||||
15 | Merck & Co., Inc. (MSD) |
0
1
2
3
4
5
|
1.28 | |
Merck & Co., Inc. (MSD)Read more |
||||
16 | Bristol Myers Squibb Co. |
0
1
2
3
4
5
|
1.19 | |
Bristol Myers Squibb Co.Read more |
||||
17 | Bayer AG |
0
1
2
3
4
5
|
1.01 | |
Bayer AGRead more |
||||
18 | Novo Nordisk A/S |
0
1
2
3
4
5
|
0.98 | |
Novo Nordisk A/SRead more |
||||
19 | Eli Lilly & Co. |
0
1
2
3
4
5
|
0.88 | |
Eli Lilly & Co.Read more |
||||
20 | Daiichi Sankyo Co. Ltd. |
0
1
2
3
4
5
|
0.84 | |
Daiichi Sankyo Co. Ltd.Read more |
0
1
2
3
4
5
|
The ranking above shows the position and score of each company in the 2021 Index. Click on a company's name to go to its full report card.
Insights
-
1,073 R&D projects in the pipeline
The 2021 Index captured 1,073 R&D projects for the 82 diseases, conditions and pathogens in scope i.e., those that cause the greatest burden in low- and middle-income countries. More than 80% of people alive today live in low- and middle-income countries and face the bulk of the global burden imposed by these diseases.
-
17 companies respond to COVID-19
During the period of analysis, 17 of the 20 companies in the scope of the Index were active in R&D for COVID-19. A total of 63 projects targeting the virus were in development. The COVID-19 pandemic has demonstrated companies’ ability to rapidly mobilise in the face of priorities.
-
Over 70% of R&D priorities go unaddressed
Over 70% (149/211) of the internationally identified R&D priorities for low- and middle-income countries remain unaddressed by the companies in scope. This includes maternal health conditions such as hypertensive disorders of pregnancy and diseases such as Bunyaviral diseases, several diarrhoeal diseases and sexually transmitted infections (STIs).
-
440 R&D projects offer a clear public health benefit
The 2021 Index identified 440 projects that target a disease and/or product gap not yet established as a priority by global health stakeholders. These projects are deemed by the Index to offer a clear public health benefit for people living in low-and middle-income countries, e.g., projects aiming for heat stability or with clinical trials running in countries in scope.